Supplementary Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Authors :: Sai-Hong Ignatius Ou
Pasi A. Jänne
Takashi Seto
Yanfei Gao
Qinying Zhao
Frank Fan
Meijing Li
Chenhui Deng
Kenji Nakamaru
Takeshi Isoyama
Masaya Tachibana
Hiroyuki Hanzawa
Naoki Nakao
Giorgio Senaldi
Alexa B. Schrock
Russell Madison
Heather A. Wakelee
Thomas Yang Sun
Viola W. Zhu
Yuki Shimizu
Ryohei Katayama
Alice T. Shaw
Erkut Borazanci
Kyriakos P. Papadopoulos
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplemental tables and figures

Tools